ArticleBiomedical chromatography : BMC2026
LC-MS/MS Method for Quantifying the Alterations of Four Neurotransmitters in Plasma From Insomnia Patients Treated With Zhibai Anshen Oral Liquid.
Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Zhibai Anshen (ZbAs) oral liquid is employed to alleviate insomnia. However, the neurotransmitters in this treatment are insufficiently investigated. This study aimed to establish a method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for determination of 5-hydroxytryptamine (5-HT), dopamine (DA), epinephrine (E), and norepinephrine (NE) in the plasma of patients treated with ZbAs. Plasma samples were processed by protein precipitation with acetonitrile containing internal standard linezolid. Insomnia patients were enrolled and treated with ZbAs, and the plasma samples were collected at baseline and end of treatment. The Pittsburgh Sleep Quality Index (PSQI) was retrieved and the concentrations of neurotransmitters were quantified. The method was successfully developed and validated. It was successfully applied to analyzing plasma samples from 51 patients, revealing a significantly increased level of 5-HT and obviously decreased levels of NE and DA after treatment, while the E kept steady against ZbAs. The PSQI significantly decreased after ZbAs treatment (21.63 ± 6.94 vs. 16.44 ± 7.17, p = 0.0006). A rapid, simple, and sensitive LC-MS/MS method for the determination of four neurotransmitters was established. ZbAs showed satisfying efficacy in treating insomnia, accompanied by obvious alterations of three neurotransmitters, which may be regarded as indicators for efficacy assessment of ZbAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.